Key result
Levosimendan improved cardiac index (2.8 vs 2.3 l/min/m²) and significantly reduced ICU length of stay (52 vs 60 hours) and 30-day mortality (3.33% vs 10%) compared to dobutamine in patients with low cardiac output syndrome after cardiac surgery.
Why the study?
The use of levosimendan in the treatment of low cardiac output syndrome pre- and postoperatively after cardiac surgery under extracardiac circulation is poorly documented.
Does levosimendan improve hemodynamics and clinical outcomes compared to dobutamine in patients with low cardiac output syndrome undergoing cardiac surgery?
Cohort (n=60)
Does levosimendan improve hemodynamics and clinical outcomes compared to dobutamine in patients with low cardiac output syndrome undergoing cardiac surgery?
Absolute Event Rate: 2.8% vs 2.3%
Levosimendan improves cardiac index compared to dobutamine in patients with low cardiac output syndrome after cardiac surgery.
May support levosimendan for post-surgical low-output hemodynamics; hypothesis-generating and leaves open outcome benefits versus dobutamine.
Introduction: levosimendan is an inodilator successfully used in the treatment of acute and chronic heart failure. Its use in the treatment of low cardiac output syndrome pre- and postoperatively after cardiac surgery under extracardiac circulation is poorly documented, but it appears to be a very interesting alternative in terms of morbimortality. Aim of the study: to evaluate the value of levosimendan versus dobutamine in the rapid weaning of inotropic drugs in low output patients awaiting cardiac surgery and after surgery under extracorporeal circulation. Materials and methods: sixty patients with low cardiac output syndrome before surgery on levosimendan and after cardiac surgery on extracorporeal circulation, requiring positive inotropic and vasopressor drugs (dobutamine ± noradrenaline). Post-operatively, in the context of drug weaning, we identified two groups : levosimendan group (n=30) and dobutamine group (n=30). In the levosimendan group, dobutamine was replaced immediately postoperatively by levosimendan. Hemodynamic parameters (MAP, HR, CI, ESV, SVR), ICU length of stay and 30-day mortality were assessed and compared between the two groups of patients. Results: Cardiac index was significantly higher in the levosimendan group than in the dobutamine group (2.8 [0.3] l/min/m² versus 2.3 [0.4] ml/min/m²) respectively, P Conclusion: the use of levosimendan in the treatment of low cardiac output syndrome before and after cardiac surgery with extracorporeal circulation resulted in rapid improvement in hemodynamic status with a short intensive care unit stay and low mortality.
No takes yet. Share an insight, caveat, or question.
Abdelbaki et al. (2023) conducted a cohort in Low cardiac output syndrome (n=60). Levosimendan vs. Dobutamine was evaluated on Cardiac index (l/min/m²). Levosimendan improved cardiac index (2.8 vs 2.3 l/min/m²) and significantly reduced ICU length of stay (52 vs 60 hours) and 30-day mortality (3.33% vs 10%) compared to dobutamine in patients with low cardiac output syndrome after cardiac surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: